Entropy NeurodynamicsASX: ENP

Actual: Aug 1, 2022

Phase 2a BED first patient results: >80% average reduction in binge eating episodes; no drug-related adverse events (NCT05035927, University of Florida)

Why it matters: TRP-8802 achieved >80% reduction in binge eating episodes — a dramatic effect size for a disorder with limited approved treatments (only lisdexamfetamine). This is the first controlled psilocybin trial in binge eating disorder.

Actual: Jan 1, 2025

Phase 2a fibromyalgia: improvements in pain severity, sleep, and pain interference in all 5 patients; results published in Frontiers in Pain Research 2025 (NCT05128162, University of Michigan)

Why it matters: Fibromyalgia is one of the most treatment-resistant chronic pain conditions. 100% responder rate in the Phase 2a, with results published in a peer-reviewed journal, is a strong signal for Phase 2b development.

Watch next: Phase 2b fibromyalgia trial design and initiation

Actual: Dec 1, 2025

First patient dosed in world's first IV psilocin clinical trial (Swinburne University, Melbourne, Australia; ANZCTR registered)

Why it matters: TRP-8803 delivers psilocin (the active metabolite of psilocybin) by IV infusion over 140 minutes, bypassing the variable prodrug conversion step and enabling precise, real-time dose titration. This is the first human data on IV psilocin — critical for understanding the dose-response relationship without oral absorption variability.

Watch next: Cohort 1 safety/tolerability/PK results; Cohort 2 completion; fibromyalgia and IBS extensions